Characterization of the Newly Established Homoharringtonine- (HHT-) Resistant Cell Lines and Mechanisms of Resistance

Table 1

Comparison of the CALCRL expression characteristics of AML patients between low group and high group.

Variables	CALCRL expression		value
	Low group	High group
Number, n (%)	130 (67)	43 (33)
Age, median (range)	51.5 (18,80)	51 (14,69)	0.647
Female, n (%)	55 (42.3)	21 (48.8)	0.482
WBC^1, median (range)	13.4 (0.2, 453.2)	37.5 (0.9, 214.0)	0.235
HB^2, median (range)	81.0 (33.5, 154.0)	74.0 (53.0, 134)	0.090
PLT^3, median (range)	42 (2, 776)	44 (4, 778)	0.736
BM^4 blast, median (range) %	69 (17.5, 96.65)	67.2 (23, 95)	0.645
FAB^5 type			0.447
M0	8 (6.2)	3 (7.0)
M1	13 (10.0)	2 (4.7)
M2	53 (40.8)	24 (55.8)
M4	6 (4.6)	3 (7.0)
M5	40 (30.8)	10 (23.3)
M6	4 (0.1)	0 (0)
Karyotype risk^6,n (%)			1.000
Favorable	5 (3.8)	1 (2.3)
Intermediate	105 (80.8)	38 (88.4)
Unfavorable	6 (4.6)	2 (4.7)
Gene mutation
FLT3-ITD	18 (16.2)	26 (23.4)	0.002
NPM1	24 (21.6)	38 (34.2)	0.693
CEBPA^DM7	19 (17.1)	13 (11.7)	1.000
IDH1	5 (4.5)	14 (12.6)	0.375
IDH2	9 (8.1)	12 (10.8)	0.778
DNMT3A	7 (6.3)	16 (14.4)	0.775

¹WBC, white blood cell; ²HB, hemoglobin; ³PLT, platelet counts; ⁴BM, bone marrow; ⁵FAB, French-American-British classification systems; ⁶karyotype risk. Favorable subgroup comprised t (8, 21)/AML1-ETO, inv16 or t (16, 16)(p13.1; q22)/CBFb-MYH11,CEPRA^DM, NPM1 without FLT3-ITD or FLT3-ITD^low. Adverse group consisted of t (8, 16), inv (3)/t (3, 3), −5, −7, del (5q), del (7p), 11q23, and complex translocations. Intermediate subtype contained cytogenetically normal and AML with other cytogenetic abnormalities. ⁷DM, double-allele.